[Corrections] Corrections

Schwameis M et al. Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 effi cacy trial. Lancet Infect Dis 2017; 17: 322 –29—In the affiliations, L Meinel's qualification should have been PhD. In the Outcomes section of the Methods, the second sentence of the second paragraph should have read “Treatment failure was defined as seroconversion (IgM, IgG, or both), appearance of erythema migrans throughout the study participants seronegative at baseline (IgM, IgG, or both), or both seroconversion and erythema migrans throughout the study.
Source: The Lancet Infectious Diseases - Category: Infectious Diseases Tags: Corrections Source Type: research